key: cord-0885422-1r5op5zi authors: MILLION, Matthieu; ROUSSEL, Yanis; RAOULT, Didier title: Chloroquine and COVID-19: A Western Medical and Scientific Drift? date: 2020-06-23 journal: Eur J Intern Med DOI: 10.1016/j.ejim.2020.06.020 sha: 11a9e10e64e9bfdffbebe3b2d3ac88eb21b77bab doc_id: 885422 cord_uid: 1r5op5zi nan We read with interest the letter entitled "COVID-19 and hydroxychloroquine: is the wonder drug failing ?" by U. Paliani and A. Cordona (1) . This work illustrates the need to be very careful in analyzing the literature at a time when scientific conflicts of this magnitude are taking place. Chloroquine and hydroxychloroquine have moved beyond their practical aspects as drugs or as potential toxic substances to become a clash on several fronts. The countries of the South use hydroxychloroquine and chloroquine on a massive scale, just as they used them before for malaria, or still use them now for systemic lupus erythematosus and rheumatic diseases. And, as more than 2 billion people at least have used this treatment, they have the greatest difficulty in believing that this product has become, by 2020, an extremely toxic product. Coincidentally or as a consequence, the countries with the highest mortality from COVID-19 are also the countries that have demonized chloroquine the most, i.e. Western Europe and part of the United States. There is therefore a geographical pro-or antichloroquine correlation, on the one hand North-South, on the other hand West-East, which is beyond scientific data. A total of 4.6 billions of people live in countries where chloroquine or hydroxychloroquine are recommended for COVID-19. When there is such a tension in the analysis of the data, one has to be careful, and for example, some of the references (2) given in this article have now been retracted by the journal(3), then by 3 of the 4 authors (4) because the data presented were either manipulated or entirely invented. On the other hand, we have recently completed a meta-analysis that includes all comparative studies evaluating chloroquine derivatives (5) . On this occasion, we discovered that even in the British Medical Journal (6) the editorial office had asked to remove from the original paper (7) leads to the retraction of the work, or sometimes to its radical questioning in this period of extreme tension around chloroquine. In practice, it is necessary to avoid drawing conclusions too quickly without an exhaustive research of the work carried out before concluding. COVID-19 and hydroxychloroquine: is the wonder drug failing ? Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial Hydroxychloroquine in patients with COVID-19: an open-label, randomized No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative meta-analysis between the Big data and the real world A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19